[8-K] Olema Pharmaceuticals, Inc. Reports Material Event

Rhea-AI Filing Summary

Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.

The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.

Positive

• Press release furnished (Exhibit 99.1) reporting quarter results, indicating formal disclosure to the market
• Investor presentation furnished (Exhibit 99.2) and made available on the company website to support investor review
• Interactive data file included (Exhibit 104), facilitating standardized access to cover page data

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine disclosure furnishing quarterly results; no financial details are included in the 8-K itself.

The filing serves primarily to notify the market that Olema has released its quarter-end results and supporting investor materials. Because the 8-K text contains no revenue, EPS, cash flow, or guidance figures, there is no basis within this filing to assess operational performance or revalue forecasts. Material analysis requires reviewing Exhibit 99.1 and 99.2.

Investor Relations Specialist

TL;DR: Communication-focused filing; exhibits and website posting improve accessibility but do not alter fundamentals.

Furnishing both a press release and an investor deck is consistent with standard disclosure practice and helps ensure broad distribution of results to shareholders and analysts. The distinction that materials are "furnished" rather than "filed" is typical and limits certain legal liabilities but does not change the availability of the disclosed content. Impact is informational rather than material in isolation.

false000175028400017502842025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Olema Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39712	30-0409740
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
780 Brannan Street
San Francisco, California				94103
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 415 651-3316

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		OLMA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On August 11, 2025, the Company also made available on its website a copy of the Company’s presentation to be shared with investors and others from time to time. The presentation is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, and in Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 11, 2025, of Olema Pharmaceuticals, Inc.
99.2		Investor Presentation, dated August 11, 2025, of Olema Pharmaceuticals, Inc.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			OLEMA PHARMACEUTICALS, INC.
Date:	August 11, 2025	By:	/s/ Shane Kovacs
			Shane Kovacs Chief Operating and Financial Officer

FAQ

What did Olema (OLMA) disclose in this 8-K?

The company reported it released financial results for the quarter ended June 30, 2025 and furnished a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2).

Are the press release and investor presentation filed or furnished?

The filing states the press release and presentation are furnished, not deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can I find the detailed financial figures for OLMA's quarter?

Detailed figures are contained in the attached Exhibit 99.1 press release and Exhibit 99.2 investor presentation, which the 8-K furnishes and the company placed on its website.

Which period do the disclosed results cover?

The results cover the quarter ended June 30, 2025.

What exhibits were included with the 8-K?

The filing lists Exhibit 99.1 (press release), Exhibit 99.2 (investor presentation), and Exhibit 104 (cover page interactive data file).

Who signed the report on behalf of Olema?

The report was signed by Shane Kovacs, Chief Operating and Financial Officer, as indicated in the filing.